The mechanisms that underly the regulation of human CYP1A1 have merited considerable attention because of their association both with toxic outcomes and the etiology of several cancers. Previous work conducted in this laboratory has identified a negative regulatory element (NRE) in the 5Ј region of this gene that appeared to modulate CYP1A1 transcriptional activity. This NRE is present in two functional copies, a high affinity 21-bp palindrome centered at position -784, and an additional element found within a GC-rich region between position -728 and -558. In this report, the regulatory function of the NREs in the context of the CYP1A1 promoter was evaluated. This was accomplished by substituting mutated elements for the corresponding wild-type element in a vector that contained human CYP1A1 sequences positions -1140 to ⍣59 directing the transcription of the chloramphenicol acetyltransferase reporter gene. Expression vectors containing specific mutations in each or both NREs were characterized. We show that eliminating the binding of the CYP1A1 repressor protein to one or both repressor motifs results in a significant 2-to 3-fold increase in the inducibility of CYP1A1 promoter activity. Although mutation of both sites appeared to result in an increase in inducibility over that observed with only one site mutated, the effect was not additive. Such aberrant transcriptional activity correlates with the highly inducible aryl hydrocarbon hydroxylase phenotype that is a reported marker for individuals predisposed to lung cancer. Mutation of the NRE, or more likely, the cognate repressor protein(s), may provide a genetic basis for this phenotype.
Introduction
The cytochrome P450 superfamily consists of Ͼ400 hemoproteins that catalyze the mono-oxygenation of a variety of lipophilic substances, including many xenobiotics, as well as endogenous compounds such as steroids, prostaglandins and fatty acids (1, 2) . One member of this superfamily, CYP1A1, is closely associated with aryl hydrocarbon hydroxylase (AHH*) activity (3) . Normally not expressed constitutively in adult human tissues, CYP1A1 activity is highly induced by a variety of planar lipophilic xenobiotics including polycyclic aromatic *Abbreviations: NRE, negative regulatory element; AHH, aryl hydrocarbon hydroxylase; PAH, polycyclic aromatic hydrocarbons; AhR, aryl hydrocarbon receptor; NRE, negative regulatory element; EMEM, Eagle's minimal essential medium; poly[d(I-C)], poly-deoxyinosinic-deoxycytidylic acid; CAT; chloramphenicol acetyltransferase; PBS, phosphate-buffered saline; RPA, ribonuclease protection assays; RFLPs, restriction fragment length polymorphisms.
hydrocarbons (PAH) and halogenated aromatic hydrocarbons found in tobacco smoke, other environmental contaminants, and dietary constituents. Induction also has been observed by a variety of substances that do not appear to belong to this class of compounds, such as omeprazole (4) and the insecticide, carbaryl (5) . In all instances, it has been well documented that this induction process is controlled primarily at the level of transcription (see 6 for review).
The induction of CYP1A1 or AHH activity exhibits genetic determinants. Further, a distinct phenotypic polymorphism has been reported in humans with~10% of the general population exhibiting highly inducible activity (7) (8) (9) . Given the role cytochrome P450 plays in the metabolic activation of procarcinogens and protoxicants, it has been proposed that such genetic differences might correlate with an inherent predisposition to certain cancers (10) . Indeed, early clinical investigations correlated the incidence of bronchogenic and pulmonary carcinomas with this highly inducible AHH phenotype (11, 12) . This has subsequently been confirmed by several investigators (13) . Evidence also exists that demonstrates a correlation between pulmonary CYP1A1 expression, DNA adduct formation, and smoking in lung cancer patients (14) (15) (16) (17) . In pulmonary carcinoma cell lines of various histological origins and in primary human breast cancer, aberrant constitutive expression of CYP1A1 also has been detected (18) (19) (20) . These observations suggest that the inappropriate expression of CYP1A1 reflects an alteration in one or more transcriptional control mechanisms that regulate the expression of this gene, and perhaps other genes linked to the etiology of human cancer. Clearly, a better understanding of CYP1A1 regulation will help to define its role and/or the role of factors regulating its expression in cancer predisposition, carcinogenesis, and neoplastic progression.
CYP1A1 expression is controlled at the level of transcription by the coordinate interaction of both positively and negatively acting transcription factors (21) . Of the positively acting factors, the most highly studied is the aryl hydrocarbon receptor (AhR), a member of the PAS basic, helix-loop-helix family of transcription factors (22) . In the absence of ligand, the AhR is localized in the cytosol associated with the 90-kDa heat shock protein (hsp90) and possibly two other proteins (23) . PAH and halogenated aromatic hydrocarbons bind with high affinity to the AhR, which results in a translocation into the nucleus, dissociation of hsp90 and formation of a heterodimer with the related, 84-kDa ARNT protein (24) (25) (26) . The AhR/ ARNT heterodimer binds to a modified E box recognition element, the aryl hydrocarbon responsive element (AhRE), several copies of which are found upstream of the CYP1A1 gene (27, 28) . Morgan and Whitlock (29) have proposed that upon binding of the AhR/ARNT heterodimer to one or more AhRE, the DNA helix is distorted to produce changes in nucleosome configuration and chromatin structure. As more AhREs are occupied, this altered structure extends toward the promoter. These structural changes make the basal promoter elements more accessible to their cognate transcription factors. More recently, this hypothesis has been supported by in vivo footprinting studies, although it is clear the induced structural changes do not include a complete clearing of nucleosomal structure from the promoter region (30, 31) .
Using deletion analysis, the human CYP1A1 negative regulatory element (NRE) was first localized to a 275-bp fragment (position -833 to -558) that is flanked by two positively acting, AhRE containing domains (32) . Subsequent studies have demonstrated the presence of two distinct NREs within this original fragment, an upstream element from positions -833 to -729 and a downstream element from positions -729 to -558. Both elements down-regulated a constitutively active, heterologous enhancer/promoter and bound the same factor present in HepG2 cell nuclear extract, although the upstream NRE exhibits higher affinity (33) . Using both in vitro DNA binding and transient expression assays, the binding site within the higher affinity NRE was further defined as a tripartite element, the core protein-binding region localized to a 21-bp palindrome between positions -794 and -774. The palindrome consists of an 8-bp inverted repeat separated by a 5-bp spacer and is flanked by two GC-rich boxes (33, 34) .
The studies described herein address the question of the functional significance of the NREs within the context of the CYP1A1 promoter. We show that the efficacy of the NRE is dependent upon the integrity of repressor complex formation at each binding site. Further, although both sites can function independently, some co-operative activity also is suggested by our data, though it is less than additive. Most important, the NREs appear to interact indirectly with the positive regulatory elements to control CYP1A1 inducibility.
Materials and methods

Materials
Molecular biology grade reagents, cell culture reagents including Eagle's minimal essential medium (EMEM), penicillin, streptomycin, poly-L-lysine, fetal bovine serum (FBS), and protease inhibitors (antipain, aprotinin, leupeptin, pepstatin, and phenylmethylsulfonyl fluoride) were purchased from Sigma Chemical Co. (St Louis, MO). Nuserum™ was obtained from Collaborative Biomedical Products, Becton Dickinson Labware (Bedford, MA). Superscript II™ reverse transcriptase, deoxyribonuclease I (DNase I), SP6 RNA polymerase, some restriction endonucleases, TRIzol™ and Lipofectin Reagent™ were acquired from Life Technologies, Inc. (Gaithersburg, MD). Other restriction endonucleases, T4 DNA ligase and T4 DNA polymerase were obtained from New England Biolabs (Beverley, MA). Poly-deoxyinosinicdeoxycytidylic acid {poly[d(I-C)]} was purchased from Boehringer Mannheim (Indianapolis, IN). The compound 2,3,7,8-tetrachlorodibenzofuran (TCDF) was purchased from Ultra Biochemicals (Hope, RI). Bacterial media reagents were purchased from DIFCO Laboratories (Detroit, MI). pBluescriptIIKSϩ and Escherichia coli SURE cells were obtained from Stratagene (La Jolla, CA). Micro bicinchoninic acid (BCA) protein assay reagents were acquired from Pierce Chemical Co. (Rockford, IL). [α-32 P]Deoxyribonucleotide triphosphates (dNTPs) (3000 Ci/mmol) and [α-32 P]uridine 5 triphosphate (UTP) (800 Ci/mmol) were purchased from DuPont-New England Nuclear (Boston, MA). Wizard™ Maxiprep DNA Purification resin and the Altered Sites™ In Vitro Mutagenesis System were purchased from Promega (Madison, WI). pTRI-β-actin-human antisense control template, pTRIPLEscript™ cloning vector, RPA II™ Ribonuclease Protection Assay Kits, MAXIscript™ SP6 In Vitro Transcription Kits, and CAT-direct™ Kits including the pTRI-CAT vector were purchased from Ambion (Austin, TX). Sequenase® Version 2.0 was purchased from United States Biochemical Corporation (Cleveland, OH). Radiolytic imaging to quantitate 32 P was performed using an AMBIS System and supporting software (CSPI Scanalytics, Billerica, MA). The OLIGO software package (V 4.1) was from National Biosciences, Inc. (Plymouth, MN). Oligonucleotides that were custom synthesized also were obtained from National Biosciences, Inc.
Cells and culture conditions
The HepG2 human hepatoblastoma cell line (passage 8) (35) was the generous gift of Dr B.Knowles, Jackson Laboratories. The cells were cultured in EMEM 772 supplemented with 10% FBS, 50 U penicillin/ml and 50 mg streptomycin/ml and maintained in a humidified incubator at 37°C in an atmosphere of 5% CO 2 /95% air. Cells were subcultured (1:4 ratio) every 3-4 days and used in these studies between the 12th and 20th passage.
Plasmid constructs pRNH241c contains human CYP1A1 sequences from position -1140 to ϩ59 and directs the transcription of the bacterial chloramphenicol acetyltransferase (CAT) reporter gene. pRNH302c is identical to pRNH241c except that it contains a mutation at position -739, which creates a unique AgeI restriction endonuclease site that proved useful in the design of cloning strategies. Compared with a wild-type NRE fragment or the pRNH241c wild-type vector, this mutation did not affect in vitro protein binding or in vivo function, respectively. Both vectors served as wild-type controls for the transient expression studies. pRNH261c contains a G→T point mutation at -787 in the NRE palindrome. pRNH491c contains a substitution mutation in which the sequences from positions -656 (Bpu1102) to -587 (Srf I) were replaced with inert sequences. This resulted in a change from 67 bp to 71 bp and a change in GC/AT content from 41/26 to 26/45. The inability of these inert sequences to bind HepG2 nuclear protein specifically was shown by electrophoretic mobility shift assay (data not shown). pRNH503c is identical to pRNH491c but also contains the G→T point mutation at position -787.
Several plasmids served as sources of fragments for DNA binding assays. A 178-bp ApaI/Bpu1102 fragment containing CYP1A1 sequences from position -831 to -653 was cloned as a blunt-end fragment into the SmaI site of pBluescriptIIKSϩ and referred to as pRNH347 and pRNH348 (opposite orientations). A fragment representing CYP1A1 sequences from position -656 (Bpu1102) to -583 (Srf I) was cloned as a blunt-end fragment into the SmaI site of pBluescriptIIKSϩ and referred to as pRNH470. For pRNH474c, CYP1A1 sequences from position -584 (SrfI) to -525 (Bsu36I) were eliminated from pRNH302c and a 61-bp polylinker fragment (XhoI/SpeI) from pBluescriptIISKϩ was substituted in its place. A 128-bp Bpu1102/Bsu36I fragment representing CYP1A1 sequences position -656 to -525 was cloned as a blunt-end fragment into the SmaI site of pBluescriptIIKSϩ, generating pRNH467, which was subsequently modified by eliminating sequences from position -656 to -558 (SacII) to generate pRNH479, sequences from position -656 to -583 (SrfI/SpeI) to generate pRNH480, or sequences from position -550 to -525 (NarI/Bsu36I) and sequences from position -656 to -583 (SrfI/ SpeI) to generate pRNH481. In all instances, plasmid DNA was used to transform E.coli SURE cells following the method of Hanahan (36) and was isolated from large scale cultures using the method of Tartof and Hobbs (37) . Final purification was achieved using the Wizard reverse phase resin from Promega.
Site-directed mutagenesis
Mutagenesis of the CYP1A1 NRE -784 palindrome was accomplished by oligonucleotide-directed mutagenesis using the pAlter™ vector as described earlier (38) . The presence of the desired mutation(s) and the integrity of the remaining DNA fragment were verified by dideoxy sequencing (39) . The presence and orientation of inserts in the various constructs were verified by both restriction endonuclease and DNA sequence analysis.
Electrophoretic mobility shift assays (EMSA)
For EMSA, DNA sequences corresponding to positions -833 to -656 were isolated as a 200-bp EcoRI/BamHI fragment from pRNH347 or as a 177-bp ApaI/Bpu1102 fragments from pRNH241c and subclones containing point mutations. DNA sequences corresponding to -833 to -739 were isolated as a 105-bp EcoRI/AgeI fragment from pRNH348. Sequences corresponding to positions -794 to -774 were isolated as a 45-bp EcoRI/BamHI fragment from pRNH209 (34) . DNA sequences corresponding to positions -656 to -587 were isolated as a 92-bp EcoRI/BamHI fragment from pRNH470 or as a 77-bp Bpu1102/BamHI fragment from pRNH474c. DNA sequences corresponding to positions -587 to -527 were isolated as an 80-bp EcoRI/BamHI fragment from pRNH480, from positions -587 to -555 as a 55-bp EcoRI/XbaI fragment from pRNH481, and from position -559 to -528 as a 57-bp EcoRI/SstI fragment from pRNH479. The oligonucleotide, 5Ј-GAA GTT TTA CCT CAG GGA GGG C-3Ј and its complement were annealed to create a consensus binding sequence for the YY1 transcription factor (40, 41) . A nuclear extract from HepG2 cells was prepared and EMSA performed using the method of Chodosh (42) with the modifications described earlier (33) . Competitive EMSA was done as described by Boucher et al. (34) and the data analyzed by linear regression using the INSTAT software package (Graphpad Software). Protein concentration was determined using the micro BCA protein assay (43) .
Transient transfection and expression assays
At 16 h before harvesting cells in preparation for transfection, HepG2 cell cultures were fed with EMEM plus 10% FBS. Cells from a confluent flask were collected following trypsinization and dispersed by passing through a small bore pipette. Cells were resuspended in EMEM plus 5% Nuserum™ to a concentration of~100 000 cells/ml. Cells were plated on 100-mm Corning dishes pre-treated with poly-L-lysine in phosphate-buffered saline (PBS) (32) and subcultured for~24 h before transfection. At the time of transfection, cells were~60% confluent, well spread and uniformly distributed. Transfection was accomplished using a modification of the lipofection procedure described by Felgner et al. (44) and Rose et al. (45) . Lipofectin® was complexed with plasmid DNA according to the supplier's suggestion with minor modifications as follows: plasmid DNA was diluted in EMEM and combined with an equal volume of diluted Lipofectin, vortexed briefly and incubated at room temperature for at least 30 min. For transfection, 0.6 ml of the Lipofectin/ DNA mixture (1.2 g plasmid DNA and 7.2 mg of Lipofectin) was distributed over the cells and incubated at 37°C for~24 h. The transfection media was removed by aspiration and replaced with 10 ml of EMEM plus 10% FBS. Approximately 20 h after the media change, the cells were~85-90% confluent. At this time, they were treated with various doses of the AhR agonist, TCDF, or ethanol (diluent control) and incubated for various lengths of time. Cells were harvested by washing twice with 6 ml cold PBS and lysed directly by adding 1 ml TRIzol™ to the cell monolayer.
Isolation of total cellular RNA and DNA
Using the reagent TRIzol for nucleic acid isolation is a modification of the method described by Chomczynski and Sacchi (46) . Following the addition of TRIzol, the lysed cell suspension was recovered by scraping the plates and passing through a 25-gauge needle to shear chromosomal DNA. After phase separation by centrifugation, the crude RNA was recovered from the aqueous phase by isopropanol precipitation. The RNA sample was resuspended in DNase I digestion buffer (50 mM Tris-HCl, pH 8.0, 10 mM CaCl 2 , 5 mM MgCl 2 ) by incubation at 65°C and vigorous mixing. This total RNA preparation was treated with DNase I (2 h at 25°C) followed by a 10-min incubation at 65°C to inactivate the enzyme. RNA was then reprecipitated in the presence of 0.2 M sodium acetate and 3 vol. of ethanol, and was then stored at -20°C. DNA was recovered from the original organic phase by precipitation with ethanol and fragmented by vortexing for 10 s. The DNA was recovered by centrifugation and stored under 75% ethanol at -20°C.
Ribonuclease protection assays (RPA)
The synthesis of radioactive RNA probes for RPA used the reagents and basic protocols provided in the MAXIscript™SP6 In Vitro Transcription, RPA II Ribonuclease Protection Assay, and CAT-Direct™ kits from Ambion. Probes used for detection of the CAT (pTRI-CAT) and human β-actin (pTRI-β-acting-human) mRNA were supplied by Ambion. Differing amounts of unlabeled UTP were added during synthesis to adjust the specific activity of the probes as needed. For example, the β-actin probe generally was labeled to an~5-fold lower specific activity and was used as the internal standard RNA for normalization to total RNA loaded. Following synthesis with [α-32 P]UTP, transcripts were purified from 8 M urea, 6% polyacrylamide gels. The sizes of the full length transcripts for each probe were 271 and 200 nucleotides for the CAT and β-actin probes, respectively. Upon hybridization with total RNA and subsequent digestion with ribonucleases A and T1, protected fragments were resolved in non-denaturing gels to allow for maximum detection of probe generated signals and higher resolution of RNA-RNA duplexes. Samples were resuspended in 10% sucrose and resolved in an 8% polyacrylamide gel run in 1ϫ TBE at 50 V, 16°C for~20 h. The fragments migrated as 152 and 120 nucleotides and represented the levels of CAT and β-actin mRNA present, respectively. Riboprobes were monitored routinely to ensure that they were in excess of their intended target transcripts. For most hybridizations,~20 µg of total RNA was analyzed.
The ability to hybridize RNA to DNA and form stable heteroduplexes (47) allowed us to normalize for transfection efficiency using the same riboprobes. By employing this method, co-transfection with a second 'reference' reporter plasmid was avoided. The normalization coefficient was the actual amount of CYP1A1-CAT reporter DNA incorporated into the cells. DNA recovered from the organic phase during RNA extraction with TRIzol was hybridized with a CAT riboprobe synthesized at an~5-fold lower specific activity and subsequently processed as a routine RPA. The DNA-riboprobe heteroduplex was resuspended in 80% formamide, denatured at 100°C and resolved on an 8 M urea, 5.5% polyacrylamide gel using 1ϫ TBE as a running buffer at 250 V. The gels (denaturing and non-denaturing) were dried and exposed to Kodak X-Omat AR film in the presence of Dupont Cronex Lightning Plus intensifying screens for 24 to 48 h. Signals detected were quantified using AMBIS radiolytic imaging of phosphorous-32. For transient expression assays, the signal for CAT mRNA was normalized for total RNA loaded using the β-actin mRNA from the non-denaturing gel. This value was normalized for transfection efficiency by dividing the signal generated from the CAT DNA RPA. Statistical difference was determined using a paired Student's t-test, accepting P Ͻ 0.05 as significant.
Results
Site-directed mutagenesis of the -784 NRE palindrome (33) was used to identify the critical DNA determinants for repressor binding between positions -774 and -794. Specific sites in the -784 palindrome that were obvious targets for site-directed mutagenesis included residues identified as sites of protein contact using the methylation interference assay (33) . Another obvious target was the spacer sequence separating the 8-bp inverted repeat. The spectrum of mutations created included point transversions of residues identified by methylation interference, point transversion of residues that could not be identified using this technique, i.e. thymines potentially important for protein recognition and binding, and 2 bp and 5 bp insertions into the spacer. Because the stringency required by the repressor for specific binding was not known, combinations of point mutations were created based on the suspicion that mutation of multiple residues would be required to eliminate specific binding. This was also the goal behind making transversion mutations, as they would most drastically alter the properties of the DNA. Mutations were created primarily in the upstream half-site because it appeared to give the more highly protected footprint and strongest sites of guanine methylation interference (33) .
To characterize each mutant's ability to form a specific repressor complex, each was isolated as a 177-bp restriction endonuclease fragment containing sequences from position -833 to -656 and radiolabeled for use in EMSA. All of the sequences flanking the -784 palindrome that were previously identified as important for stable repressor binding were present in these fragments. Data are shown in Figure 1 . A subset of palindrome mutants was analyzed, including: (i) point mutation of residues in each half-site that make contact with the repressor (NREPAL1, NREPAL3 and NREPAL13); (ii) a mutation that alters spacing between the half-sites (NREPAL7); (iii) mutation of a residue in the spacer that contacts the repressor (NREPAL5); (iv) mutation of a residue with unknown relationship to the repressor (NREPAL16); and (v) a combination of two mutations (NREPAL4). Surprisingly, transversion mutations of single residues (NREPAL1, NREPAL3, and NREPAL5) abolish specific complex formation as does the insertion of 2 bp into the spacer (NREPAL7) and the double mutation (NREPAL4). Only one mutant (NREPAL13) formed a specific protein complex with a binding affinity similar to the wild-type sequence.
To assess the relative protein binding affinity of each mutated sequence, all of the mutants created were analyzed by competitive EMSA. This involved radiolabeling a fragment spanning positions -833 to -656 containing the wild-type NRE palindrome and adding, as competitor DNA, fragments that contained specific mutations in the -784 NRE palindrome at a 0-to 1000-fold molar excess over the wild-type sequence. These data are summarized in Table I . Three predominant classes of mutants were identified: those with wild-type binding activity, those with intermediate binding activity, and those with no binding activity. The primary objective for these mutagenesis studies was to create a mutation in the repressor recognition motif that would effectively eliminate specific protein binding to these sequences. As anticipated, residues determined by methylation interference in contacting the repressor protein (33) were absolutely required for protein binding. Whether these residues are 'invariant' in the consensus sequence for the CYP1A1 repressor will likely depend in part upon the composition of flanking residues. a A portion of these data were presented as simple competition curves in Boucher et al. (34) . b Mutant sequences are shown below the wild-type sequence. The first 3Ј nucleotide is at position -774 of the CYP1A1 promoter. Altered residues representing point transversion mutations are indicated in italics and bold. Inserted residues are indicated in lowercase, italics and bold. c DNA fragments, corresponding to positions -833 to -656 of the human CYP1A1 promoter and containing the indicated point mutations in the -784 palindrome were used as unlabeled competitor DNA at a 0-to 1000-fold molar excess over the wild-type probe (also position -833 to -656). The radioactivity present in specific complex B was quantitated (Materials and methods), the percent competition calculated and the latter plotted against the log of the fold molar excess over the wild-type probe. After analysis by linear regression, the fold molar excess of competitor DNA necessary to inhibit specific protein binding to the wild-type probe by 50% was calculated (IC50). This same plot was used to calculate the amount of specific DNA-protein complex remaining at a 500-fold excess of unlabeled competitor DNA.
To characterize the downstream repressor sequences further and localize the second repressor binding site, a series of overlapping restriction fragments containing CYP1A1 sequences from positions -656 to -528 were evaluated by competitive EMSA with the -784 NRE palindrome. Only the sequences between positions -656 and -587 could compete for the formation of the specific repressor complex (data not 774 shown). To determine whether these sequences could form the same protein complex, they were isolated and analyzed by EMSA. Using a probe containing CYP1A1 promoter sequences from positions -656 to -587, two specific protein DNA complexes were observed (Figure 2 ). One complex migrated at a position identical to that observed with a probe containing the -784 palindrome (compare with EMSA in Figure 1 ) and Fig. 2 . Characterization of CYP1A1 sequences -656 to -587 by EMSA. A fragment that contained NRE sequences from the human CYP1A1 promoter (position -656 to -587) was isolated as a 77-bp restriction fragment and radiolabeled as a DNA probe. The migration of this probe in the absence of HepG2 nuclear extract is shown in lane 1 and labeled P. Upon addition of HepG2 nuclear extract, two specific complexes were observed (lane 2), labeled as B for the slower migrating complex and Y for the faster migrating complex. Unlabeled DNA probe was added as competitor DNA at a 25-to 500-fold molar excess (lanes 3-7) . Competitor DNAs used in lanes 8 and 9 were used at a 500-fold molar excess and represent restriction endonuclease fragments that contain sequences similar to the -784 NRE palindrome, but centered at positions -573 and -542 (Materials and methods). Lane 9 represents competition with a 500-fold molar excess of a restriction endonuclease fragment spanning from position -587 to -528. Competitor DNAs used in lanes 11 and 12 were used at a 500-fold molar excess and represent a 45-bp restriction fragment (lane 11) and a doublestranded 24-bp oligonucleotide (lane 12), which represent the-784 NRE palindrome. Lane 13 demonstrates competitive binding with a 500-fold molar excess of a consensus sequence to the YY1 transcription factor. Reactions contained~50 000 c.p.m. and 0.1 ng DNA probe and 10 g HepG2 nuclear extract.
was therefore tentatively designated complex B. A second, faster migrating specific complex also formed on this probe and was designated complex Y. Previous studies had implicated the possible involvement of a sequence similar to the -784 palindrome centered at position -573 (33) . More recently, a second similar sequence was identified at -542 (unpublished observation). However, these elements alone, or together on one fragment, could not compete for specific protein binding (Figure 2, lanes 8-10) . The assumed identity of complex B was confirmed by competitive binding assays. The specific complex formed was significantly diminished by the addition of either a 45-bp restriction fragment containing CYP1A1 promoter sequences from position -794 to -774 ( Figure 2, lane  11) or a 24-bp double-stranded oligonucleotide (Figure 2 , lane 12) that corresponded to the same palindromic element. Based on this evidence and the previous competition studies, it was concluded that complex B contained the same proteins that bind the -784 palindrome. Within the -656 to -587 fragment, a sequence identical to the YY1 transcription factor binding site in the c-fos gene was identified at position -635 to -625 (41) . Given the involvement of this transcription factor in the negative regulation of c-fos (41) , it was of interest to determine whether this factor could bind the CYP1A1 -657 to -587 fragment. A 500-fold molar excess of an oligonucleotide representing the c-fos element competed specifically with complex Y, but not complex B (Figure 2, lane 13) . Further characterization of the -657 to -587 element, including the possible involvement of YY1, is the focus of current studies in this laboratory.
The CYP1A1 promoter is highly complex, being tightly regulated by a hierarchy of transcription factors (for review see ref. 6 ). Because promoter context can contribute significantly to the binding and function of transcription factors, the analysis of NRE mutations within the context of the CYP1A1 promoter was necessary to understand the mechanism(s) by which the NRE regulates the transcriptional activities of this gene. More specifically, these studies would determine the functional relationship of the NRE to the prominent positive regulatory motifs, including inducible and basal transcription elements. The wild-type expression plasmid used for all transient CAT expression assays, pRNH241c, contains the CYP1A1 promoter/ exon 1 sequences (positions -1140 to ϩ59) and directs the transcription of the bacterial CAT reporter gene. To begin elucidating the mechanisms by which the NRE and its cognate repressor protein(s) function within the context of the CYP1A1 promoter, specific mutations previously shown to abolish repressor binding were substituted for the wild-type sequences in the CYP1A1 promoter to preserve as much of the wild-type sequence as possible. In this way, the most precise correlation between repressor binding and transcriptional activity of the CYP1A1 promoter could be determined.
The G→T transversion mutation at position -787 in the upstream half-site of the NRE palindrome resulted in a complete loss of specific repressor protein binding activity (Table I and Figure 1, NREPAL1) . In separate studies, this point mutation abolished NRE repressor activity toward a heterologous enhancer/promoter expression vector (34) . A fragment containing this point mutation was subcloned into the CYP1A1-CAT expression vector, pRNH241c, to yield a reporter plasmid identical to the parent vector except for this single base substitution. This variant was designated pRNH261c. As a first approach toward characterizing this mutant's transcriptional activity, a time course and doseresponse study for induction in the presence of the AhR agonist, TCDF, was conducted. These data are presented in Figure 3 . Because treatment with AhR agonists resulted in the near immediate generation of CYP1A1 mRNA transcripts, a 1-to 6-h time course was first evaluated. At each endpoint examined, a greater steady-state concentration of CAT transcripts was seen from the mutated promoter. Based on these and similar data (not shown), a 4-h endpoint was chosen for the subsequent dose-response study. Figure 3A -D is a composite of the results of one such assay and includes autoradiographs of a native RPA gel for CAT and actin transcript levels ( Figure 3A) , a denaturing RPA gel for CAT vector DNA as a measure of transfection efficiency ( Figure  3B ), and finally, graphical representation of normalized doseresponse and time-course data following quantitative analysis ( Figure 3C and D) . These studies compare the transcriptional activity of the NRE mutant, pRNH261c, to that of the wildtype expression vector, pRNH241c. Although these data only represent single determinations, a trend of increased transcriptional activity resulting from the NRE mutation was obvious. These dose-response studies were repeated several times under various experimental conditions to show reproducibility of this trend. The data were adjusted for probe specific activity, compiled and analyzed statistically (Figure 4) . This study clearly shows that this single base substitution results in a significant,~2-fold increase in TCDF-induced transcriptional activity. Moreover, a similar, significant increase in transcriptional activity was evident at each dose-analyzed (1, 3 and Fig. 4 . Effect of a point mutation in the -784 NRE on CYP1A1 promoter activity: a composite of RPA analysis. Transfections and RPA analysis were conducted as described in Figure 3 . The plotted data represent the transcriptional activity of the wild-type pRNH241c (s) or NRE point mutant pRNH261c (d) after a 4-h exposure to TCDF at 0, 1, 3 or 10 nM. Transcriptional activity is expressed as c.p.m. CAT mRNA normalized to the amount of actin mRNA and the amount of transfected CAT DNA. Data points represent the mean Ϯ standard deviation (n ϭ 3-7) compiled from four individual experiments. Significance levels are indicated above the error bars as *P Ͻ 0.02 and **P Ͻ 0.002. 10 nM). To show that the observed increase in this construct's transcriptional activity was caused by the specific point mutation abolishing repressor binding, two additional point mutations were analyzed as controls. These included another mutation that abolished repressor binding, (the C→T mutation at -786, NREPAL5) and one that did not affect repressor binding (the C→A mutation at -789, NREPAL13). The results of these studies were consistent with the conclusion that only point mutations in the -784 NRE palindrome that eliminate specific binding result in increased transcriptional activity (data not shown).
The data presented in Figures 3 and 4 clearly show a strong correlation between specific repressor binding to the -784 NRE palindrome in vitro and its ability to suppress transcription within the context of the CYP1A1 promoter in intact cells. In Figure 5 , the downstream repressor sequences were similarly analyzed to determine the relationship between repressor binding to these sequences and transcriptional activity. Repressor binding to these sequences was effectively eliminated by substitution of the wild-type sequences from position -656 to -587 with inert sequences of similar GC content (pRNH491c). Characterization of the transcriptional activity of this NRE mutant was conducted as described for pRNH261c. During the initial analysis of the pRNH491c promoter, the activity of the endogenous CYP1A1 gene also was analyzed as a control to demonstrate that the presence of exogenous CYP1A1 promoter sequences would not interfere with the normal regulation of the CYP1A1 gene. These control studies showed that under our experimental conditions, the endogenous CYP1A1 gene is transcriptionally silent and rapidly induced by the addition of TCDF, in synchrony with the transiently transfected gene (data not shown). Analysis of the pRNH491c expression vector relative to a wild-type construct is depicted in the composite graph ( Figure 5 ). As with mutation of the upstream repressor (pRNH261c, Figures 3 and 4) , mutation of the downstream repressor element resulted in a significant 1.5-to 2-fold increase in TCDF-inducible transcriptional activity at all doses examined.
Once the functional activity of each NRE was characterized, an NRE mutant combining these two very specific mutations was constructed. This mutant was designated pRNH503c and contains the single-base substitution of a G→T at position -787 and the 69 bp substitution of sequences from positions -656 to -587. Combining these two mutations appeared to result in a further increase in inducibility. Figure 6 is a composite of the data pooled from five independent experiments in which the transcriptional activity of the double NRE mutant (pRNH503c) was compared with that of the wild-type pRNH241c following a 4-h exposure to various doses of TCDF. The data show a highly significant (P Ͻ 0.001) increase in the transcriptional activity of the mutant CYP1A1 promoter relative to the wild-type promoter at each dose examined. The fold-increase in promoter inducibility was 2.3-fold at the 1 nM dose and 1.75-fold at the 3 and 10 nM doses. By specifically eliminating repressor binding at each copy of the NRE, the inducible activity of the CYP1A1 promoter significantly increased relative to the wild-type promoter and appeared to be enhanced compared with either single mutation.
Discussion
A role for CYP1A1 and/or factors regulating the expression of this gene in the predisposition, initiation and/or progression of human malignancies has been long recognized, but poorly understood (12, 19, 48, 49) . Research efforts that have focused on the positive regulation of CYP1A1expression have failed to identify mechanisms that might contribute to these observed aberrations in gene expression. Our studies have focused on the negative regulation of this gene as a potential mechanism that underlies aberrant CYP1A1 transcriptional activity. Earlier reports have described evidence for negative regulation being mediated by protein binding at two adjacent motifs in the human CYP1A1 promoter: a palindromic element centered at -784, and a region downstream localized to a GC-rich domain between positions -728 and -558 (33). The studies described in this manuscript used mutational analysis to elucidate the molecular mechanism(s) by which the NRE and its cognaterepressor function. Through mutation of the cis-recognition element of the CYP1A1 repressor, specific DNA binding was abolished in vitro (Reference 34 and Figure 1 ). Previous studies demonstrated that this loss of repressor binding to the -784 NRE palindrome abrogates repressor activity toward a constitutively active enhancer/promoter construct (34) . It remained to be determined whether loss of repressor binding to one or both copies of the NRE would also result in altered repressor functions within the context of the CYP1A1 promoter. A single base mutation in the CYP1A1 promoter that results in loss of repressor binding at the -784 palindrome resulted in a significant, 1.7-fold increase in promoter inducibility. An identical effect was observed by substitution of the repressor binding site between position -656 and -587 with inert sequences. This increase in transcriptional activity was evident following administration of 1 nM TCDF, the lowest dose of AhR agonist examined in these studies. Although this difference appeared even more apparent when both mutations were combined, resulting in a 2.3-fold increase in promoter activity, the elimination of the function of both NREs clearly does not yield an additive effect. Besides the increase in the maximal inducibility of the CYP1A1 promoter, these data are consistent with mutations in the NRE shifting the dose-response for transcriptional activation of the promoter by the ligand-activated AhR, particularly when both NREs were mutated. However, definitive proof for this awaits similar studies at lower doses of TCDF.
Correlations between PAH exposure and covalent DNA damage have been observed in tissues of smokers (50) and foundry workers (51) . Similarly, correlations between active cigarette smoking and CYP1A1 expression in normal and cancerous lung tissues have been described (50, 52) . Most recently, these events have been linked mechanistically in a report that characterizes the association between PAH exposure, AHH activity in target tissues and DNA adduct levels in those tissues (15) . Combined with our findings, these observations suggest that the increased inducibility of the NRE mutants at low doses of TCDF may be especially relevant when considering occupational, recreational and environmental sources of procarcinogens. A deficiency in repressor function that results in increased CYP1A1 transcription and enzyme activity would have serious implications for individuals that experience chronic low level exposures, such as those described above. In such individuals, one would predict an increase in PAH metabolism and DNA-adduct formation.
At the genetic level, restriction fragment length polymorphisms (RFLPs) have been described for the human CYP1A1 gene (53) (54) (55) . A variety of studies have been published that discuss the functional significance of these different CYP1A1 genotypes (53, 56, 57) . However, linkage of known genetic alterations to variability in CYP1A1 gene expression and in turn to an increased disease susceptibility remains controversial. The only definitive marker that shows a strong correlation to cancer susceptibility is the highly inducible AHH phenotype (11, 12, 48) . Unfortunately, identification of a genetic basis for this phenotype in the human population at either the CYP1A1 or AhR locus has not been possible. Clearly, a molecular understanding of the highly inducible AHH phenotype would have many prognostic, diagnostic, and perhaps therapeutic benefits. Given that CYP1A1 expression is controlled almost exclusively at the level of transcription, current research has focused on understanding the multiple regulatory mechanism(s) involved, thereby trying to establish a link to this phenotype.
The NRE mutations evaluated in these studies have been characterized for their effect on CYP1A1 inducibility following exposure to AhR agonists. The observed increases in the inducible activity of these mutants are remarkably similar to what has been described as the highly inducible AHH phenotype. Using the trimodal distribution population reported by Trell et al. (58) , the fold induction in the highly inducible group was ജ3.6, the intermediate ranged from 2.6 to 3.6 and the low was ഛ2.5. Thus, the difference between the low and highly inducible populations was~1.5-fold, which also agrees with other reports (12) . It is tempting to speculate that a loss of CYP1A1 repressor function is a factor contributing to this increase in inducibility. If true, the significance of this work would be in defining the repressor and/or NRE as an underlying genetic target responsible for the highly inducible AHH phenotype associated with a predisposition to lung cancer.
The negative regulatory activity associated with the CYP1A1 NRE and cognate repressor protein is dependent upon repressor binding activity. This has been demonstrated for both NRE binding sites in heterologous enhancer-promoter constructs (33, 34) as well as in the context of the human CYP1A1 promoter (32 and this study). The DNA bound repressor complex may function by a variety of means, including structural mechanisms that alter DNA conformation, chromatin configuration or nucleosome stabilization, by directly antagonizing the recruitment of basal transcription factors during AhRmediated induction, or directly inhibiting basal transcription factor activity. These repressor activities may result from domains of the repressor protein itself or by a protein that is tightly associated with the DNA-binding form of the repressor, i.e. a co-regulatory protein. The nucleosome/chromatin-based model for transcriptional activation of the mouse CYP1A1pro-moter described by Whitlock et al. (29) (30) (31) 59 ) has been widely accepted as a general mechanism for CYP1A1 transcriptional regulation. In this model, the basal transcription element of the CYP1A1 promoter is inaccessible to basal transcription factors as they are configured in a nucleosome. Upon the binding of activated AhR to its consensus sequences, localized graded changes in chromatin structure occur, which results 778 in a generalized destabilization of the chromatin-associated domains and unfolding of nucleosomal DNA at the enhancers. This allows for the subsequent looping out of the DNA to enable the DNA-bound AhR to become associated with the basal promoter elements. The C-terminal Q-rich domain of the AhR that encodes a latent transactivating function is subsequently able to communicate the transcriptional activation signal to the basal promoter elements. Under these circumstances, the basal promoter becomes protein bound in the regions corresponding to the NF-1 site and TATA box and allows for the formation of the RNA polymerase II preinitiation complex. Interestingly, the region between the upstream (position -1080 to -897) and the downstream (position -501) enhancers that correspond to the human CYP1A1NRE, remains nucleosome bound. Transcriptional repression in this model is caused by the presence of stable chromatin-associated structural elements that govern the architecture of the basal promoter. In keeping with this general model, the NRE repressor complex may facilitate transcriptional repression by stabilizing these structural elements. Furthermore, AhR-mediated transcriptional activation may be attenuated by the repressor through localized nucleosome stabilization or by interference with the Q-rich transactivating domains of the AhR. Consistent with the former hypothesis, the repressor binding motifs are located~180 bp apart: the distance incorporated in one nucleosome core. This spacing would orient the bound proteins on the same side of a nucleosome and perhaps stabilize such a complex. Also consistent with this hypothesis, the YY1 transcription factor implicated in this study as binding to the downstream NRE, is known to function as a repressor by effecting DNA structure (41) . Consistent with the hypothesis of direct interference with the AhR, both copies of the NRE are situated between two AhREs: one at position -897 (113 bp upstream of the repressor binding site at the -784 NRE palindrome) and the other at position -501 (~120 bp downstream of the repressor binding site from positions -656 to -587). Both AhREs are within 50 bp of an Sp-1 site (at positions -947 and -449) and both have been shown to function on the human CYP1A1 gene (32) . The alignment of these cis-elements in a helical, nucleosomal array would support a model that involves coordinated interactions among each element's cognate trans-acting factors and a concerted mechanism for modulating CYP1A1 transcriptional activity. These studies do not directly address the question whether the repressor protein might interact directly with the DNA bound AhR transcription factor complex. However, earlier studies in this laboratory clearly showed such a proteinprotein interaction was not mandatory for repressor function (33, 34, 60) .
In summary, we have employed a mutational approach to define a specific role for the CYP1A1 NRE and cognate repressor protein in the modulation of CYP1A1 inducibility. Although we have yet to determine the precise mechanism(s) by which the repressor functions, it is evident from our studies that a loss in NRE function results in a net 2-to 3-fold increase in maximal promoter activity in response to AhR agonists. The studies conducted not only demonstrate aberrant negative regulation of the CYP1A1 promoter when repressor binding is eliminated by cis-element mutations, but also suggest that mutations in the repressor protein itself that would inhibit DNA-binding, protein-protein association, and/or trans-acting function would result in a lost or compromised activity. Importantly, the similarities between the transcriptional activity of the NRE mutants and the highly inducible AHH phenotype implicate genetic defects in the repressor as potentially playing a role in the basic mechanism(s) governing this phenotype. It is tantalizing to propose that aberrant CYP1A1 expression, as observed in some human malignancies, may be the result of mutations that affect the mechanism(s) by which the NRE and its cognate repressor protein regulates the expression of this or perhaps other genes.
